iA Global Asset Management Inc. Raises Stake in Eli Lilly and Company $LLY

iA Global Asset Management Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 8.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,664 shares of the company’s stock after purchasing an additional 2,100 shares during the quarter. iA Global Asset Management Inc.’s holdings in Eli Lilly and Company were worth $19,582,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares in the last quarter. Laurel Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $8,827,714,000. Jennison Associates LLC lifted its holdings in Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after purchasing an additional 226,620 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after purchasing an additional 103,119 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,087.63 on Friday. The company’s 50-day moving average price is $1,056.39 and its 200-day moving average price is $878.04. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.03 trillion, a PE ratio of 53.21, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Launched a Phase 3b dosing study for retatrutide in obesity, advancing a leading obesity candidate toward optimized dosing and broader label/market potential. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Retatrutide trial data suggest potential knee osteoarthritis symptom benefit tied to weight loss — could expand clinical and commercial appeal beyond pure weight metrics. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: SURMOUNT‑REAL UK (phase 4) will provide real‑world tirzepatide data in obesity — useful for uptake, payer conversations and long‑term market sizing. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: FDA granted Breakthrough Therapy designation to sofetabart (mipitecan) for certain platinum‑resistant ovarian cancer patients — accelerates development path and raises long-term oncology upside. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Initiated a Phase 2 oral pain program for diabetic nerve pain — diversification of pipeline into high‑unmet‑need pain indications could add medium‑term value. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Announced a Phase 1 PET tracer imaging study to broaden oncology imaging capabilities — early stage, strategic but long‑timeline impact. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Neutral Sentiment: Confirmed Q4 2025 earnings date (Feb 4) — sets the calendar for next major catalyst and likely some pre‑earnings positioning. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Market commentary pieces (buy/preview, breakout) and an explainer on why LLY is up today summarize investor enthusiasm and momentum ahead of results; useful but opinion‑driven. Why Eli Lilly (LLY) stock is up today
• Negative Sentiment: Coverage notes Novo Nordisk’s new CEO is expected to intensify competition in obesity treatments — a reminder of pricing, market‑share and reimbursement risks. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LLY. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research report on Monday, January 5th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Bank of America cut their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Finally, National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a report on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $1,174.61.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.